These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26509454)

  • 41. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.
    Younger J; Parkitny L; McLain D
    Clin Rheumatol; 2014 Apr; 33(4):451-9. PubMed ID: 24526250
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low-dose naltrexone for treatment of duodenal Crohn's disease in a pediatric patient.
    Shannon A; Alkhouri N; Mayacy S; Kaplan B; Mahajan L
    Inflamm Bowel Dis; 2010 Sep; 16(9):1457. PubMed ID: 20014017
    [No Abstract]   [Full Text] [Related]  

  • 43. Effects of naltrexone on pain sensitivity and mood in fibromyalgia: no evidence for endogenous opioid pathophysiology.
    Younger JW; Zautra AJ; Cummins ET
    PLoS One; 2009; 4(4):e5180. PubMed ID: 19365548
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Utilization of Low Dose Naltrexone for Chronic Pain.
    Poliwoda S; Noss B; Truong GTD; Creech ZA; Koushik SS; Urits I; Viswanath O
    CNS Drugs; 2023 Aug; 37(8):663-670. PubMed ID: 37505425
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dual Opioid Systems: A Simpler Explanation for Naltrexone Efficacy in Fibromyalgia.
    Gillman MA
    Pain Med; 2021 Jun; 22(6):1458-1459. PubMed ID: 32918463
    [No Abstract]   [Full Text] [Related]  

  • 46. [Limited role of naltrexone in the treatment of opiate addiction].
    van Brussel GH
    Ned Tijdschr Geneeskd; 2001 Jul; 145(30):1452-6. PubMed ID: 11503313
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical status of methylnaltrexone, a new agent to prevent and manage opioid-induced side effects.
    Yuan CS
    J Support Oncol; 2004; 2(2):111-7; discussion 119-22. PubMed ID: 15328815
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low-dose naltrexone, an opioid-receptor antagonist, is a broad-spectrum analgesic: a retrospective cohort study.
    Martin SJ; McAnally HB; Okediji P; Rogosnitzky M
    Pain Manag; 2022 Sep; 12(6):699-709. PubMed ID: 35289682
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of carfentanil and naltrexone in domestic goats (Capra hircus).
    Mutlow A; Isaza R; Carpenter JW; Koch DE; Hunter RP
    J Zoo Wildl Med; 2004 Dec; 35(4):489-96. PubMed ID: 15732589
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Research on low dosage naltrexone].
    Holmøy T
    Tidsskr Nor Laegeforen; 2011 Jul; 131(13-14):1277-8. PubMed ID: 21725378
    [No Abstract]   [Full Text] [Related]  

  • 51. Long-term effects of naltrexone on self-injurious behavior.
    Sandman CA; Hetrick W; Taylor DV; Marion SD; Touchette P; Barron JL; Martinezzi V; Steinberg RM; Crinella FM
    Am J Ment Retard; 2000 Mar; 105(2):103-17. PubMed ID: 10755174
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.
    Dunbar JL; Turncliff RZ; Dong Q; Silverman BL; Ehrich EW; Lasseter KC
    Alcohol Clin Exp Res; 2006 Mar; 30(3):480-90. PubMed ID: 16499489
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Methylnaltrexone for opioid-induced constipation.
    Belavic JM
    Nurse Pract; 2009 Mar; 34(3):6-7. PubMed ID: 19240629
    [No Abstract]   [Full Text] [Related]  

  • 54. Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
    Hammer LA; Waldner H; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2016 Jan; 241(1):71-8. PubMed ID: 26202376
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Low-dose naltrexone for treatment of multiple sclerosis: clinical trials are needed.
    Patel PN
    Ann Pharmacother; 2007 Sep; 41(9):1549-50. PubMed ID: 17623758
    [No Abstract]   [Full Text] [Related]  

  • 56. Naltrexone therapy for Crohn's disease and ulcerative colitis.
    Weinstock LB
    J Clin Gastroenterol; 2014 Sep; 48(8):742. PubMed ID: 24583747
    [No Abstract]   [Full Text] [Related]  

  • 57. Initial Findings of an Open-Label Trial of Low-Dose Naltrexone for Symptomatic Mesenteric Panniculitis.
    Roginsky G; Alexoff A; Ehrenpreis ED
    J Clin Gastroenterol; 2015 Oct; 49(9):794-5. PubMed ID: 26280708
    [No Abstract]   [Full Text] [Related]  

  • 58. [Injectable extended-release naltrexone for opioid dependence: an open label study of long-term safety and efficacy].
    Krupitsky EM; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Blokhina EA; Silverman BL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(11):49-56. PubMed ID: 25591636
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Methylnaltrexone for opioid-induced constipation in patients with advanced illness: a 3-month open-label treatment extension study.
    Lipman AG; Karver S; Cooney GA; Stambler N; Israel RJ
    J Pain Palliat Care Pharmacother; 2011; 25(2):136-45. PubMed ID: 21657861
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Methylnaltrexone: a novel approach for the management of opioid-induced constipation in patients with advanced illness.
    Diego L; Atayee R; Helmons P; von Gunten CF
    Expert Rev Gastroenterol Hepatol; 2009 Oct; 3(5):473-85. PubMed ID: 19817669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.